Stoke Therapeutics Execs to Present at Cantor Healthcare Conference
Event summary
- Stoke Therapeutics CEO Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Cantor Global Healthcare Conference on September 9, 2026, at 1:00 p.m. ET.
- Zorevunersen, Stoke’s lead investigational medicine for Dravet syndrome, is in Phase 3 clinical trials.
- Stoke has strategic collaboration with Biogen for global commercialization of zorevunersen, retaining U.S., Canada, and Mexico rights.
- Zorevunersen has received multiple regulatory designations, including FDA Breakthrough Therapy and Orphan Drug status.
The big picture
Stoke Therapeutics is positioning itself as a leader in RNA medicine, focusing on restoring protein expression for rare neurological diseases. The company’s strategic collaboration with Biogen underscores the potential of zorevunersen, which has garnered significant regulatory attention. The upcoming presentation at the Cantor Global Healthcare Conference provides an opportunity to gauge investor sentiment and clinical progress.
What we're watching
- Clinical Progress
- The pace at which zorevunersen advances through Phase 3 trials will determine its regulatory approval timeline.
- Commercial Strategy
- How Stoke and Biogen execute their global commercialization strategy for zorevunersen.
- Market Dynamics
- Whether the Breakthrough Therapy designation accelerates FDA review and approval.
Related topics